人前蛋白转化酶枯草溶菌素9抑制剂在治疗高脂血症中的研究进展

Research progress on proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of hyperlipidemia

动脉粥样硬化是一种贯穿于每个人体生命过程中的慢性疾病,其最终结局以导致动脉粥样硬化性心血管疾病(ASCVD)最为常见。而促使动脉粥样硬化(AS)发生发展的最主要因素就是高脂血症,他汀类药物是目前临床上应用最广泛、最经典的一线降脂药物,给广大病人带来了获益。但有一部分病人在充分使用他汀类降脂药物时会出现血脂仍不达标或不能耐受的情况。前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂作为临床上另外一类新型降脂药,具有总体降脂效果好、不良反应相对较少、能改善病人预后等优势,是近几年最被看好的新型降脂药物。但也存在比如价格昂贵、病人依从性差、可能出现相关并发症等劣势。该文将系统地阐述PCSK9抑制剂在治疗高脂血症的研究进展。

Atherosclerosis is a chronic disease that runs through every human life course,and its final outcome is the most common atherosclerotic cardiovascular disease(ASCVD).The main factor that promotes the development of atherosclerosis(AS)is hyperlipidemia.Statins are currently the most widely used and classic first-line lipid-lowering drugs in clinical practice and have brought benefits to the majority of patients.However,some patients may still not meet the blood lipid standard or cannot tolerate it when fully using statin lipid-lowering drugs.Through research,researchers found that a proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitor can be used as another new type of lipid-lowering drug in clinical practice,with good overall lipid-lowering effects,relatively few adverse reactions,and improved patient prognosis.It is the most promising new lipid-lowering drug in recent years.However,there are also disadvantages such as high price,poor patient compliance,and possible related complications.In this paper,we systematically review the research progress of PCSK9 inhibitors in the treatment of hyperlipidemia.